<?xml version="1.0" encoding="UTF-8"?>
<p>Since the recognition of HA protein to SA linked glycoproteins is the first step in IAV infection, effective blocking of the interaction between viral HA and SA receptor serves as a favorable target in drug design [
 <xref rid="B220-viruses-12-00376" ref-type="bibr">220</xref>,
 <xref rid="B221-viruses-12-00376" ref-type="bibr">221</xref>]. Favipiravir, a nucleotide analogue that selectively inhibits the RNA-dependent RNA polymerase, is licensed in Japan to be applied against emerging influenza viruses resistant to other antivirals [
 <xref rid="B222-viruses-12-00376" ref-type="bibr">222</xref>,
 <xref rid="B223-viruses-12-00376" ref-type="bibr">223</xref>]. Oleanolic acid (OA), a kind of pentacyclic triterpene natural product, and its analogues, as well as its derivatives, were shown to bind to HA, thus blocking the attachment of IAVs to MDCK cells [
 <xref rid="B224-viruses-12-00376" ref-type="bibr">224</xref>,
 <xref rid="B225-viruses-12-00376" ref-type="bibr">225</xref>,
 <xref rid="B226-viruses-12-00376" ref-type="bibr">226</xref>]. PVF-tet is a peptide-based HA inhibitor, which was shown to sequester HA into amphisome (fusion of late endosome with autophagosome) and protected mice from the lethal IAV infection [
 <xref rid="B227-viruses-12-00376" ref-type="bibr">227</xref>].
</p>
